A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma
ID Number 15-1578Principal Investigator(s)
Department(s) or Division(s)
Pulmonary, Critical Care and Sleep Medicine
The purpose of this study is to investigate a new study drug called dupilumab as a potential treatment for persistent asthma given by injection. This study compares the effects of dupilumab with a placebo.
Subjects may qualify to take part in this research study, because they have asthma that is persistent, and the study doctor thinks they are suitable for the study.
During the study drug treatment period, they will either receive dupilumab 300 mg or its related placebo or dupilumab 200 mg or its related placebo, administered by subcutaneous injection (injection under the skin) every 2 weeks for 52 weeks.
The randomization method is set up so the subject has a 2 in 3 chance of receiving study drug or receiving placebo; therefore they have a 66% chance of receiving study drug and 33% chance of receiving placebo.
Participation in this research study is expected to last at least 69 weeks.The total number of people expected to take part in this research study at this site is 10.
Recruiting Patients: No